Golden Reserve Retirement LLC Invests $468,000 in CVS Health Corporation $CVS

Key Points

• Golden Reserve Retirement LLC made a new investment in CVS Health, purchasing 6,784 shares valued at approximately $468,000, making CVS the 9th largest position in their portfolio.
• CVS Health reported better-than-expected earnings with $1.81 EPS, surpassing the consensus estimate of $1.46, and has an anticipated FY 2025 guidance set at 6.300-6.400 EPS.
• The company announced a quarterly dividend of $0.665 to be paid on November 3rd, which reflects a 3.5% annual yield, with a current dividend payout ratio of 74.30%.

Golden Reserve Retirement LLC purchased a new position in shares of CVS Health Corporation (NYSE:CVS - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 6,784 shares of the pharmacy operator's stock, valued at approximately $468,000. CVS Health comprises about 0.2% of Golden Reserve Retirement LLC's portfolio, making the stock its 9th largest position.

Other large investors have also modified their holdings of the company. Bell Investment Advisors Inc grew its stake in shares of CVS Health by 119.8% during the first quarter. Bell Investment Advisors Inc now owns 455 shares of the pharmacy operator's stock worth $31,000 after acquiring an additional 248 shares during the last quarter. Roxbury Financial LLC boosted its position in CVS Health by 78.3% in the second quarter. Roxbury Financial LLC now owns 460 shares of the pharmacy operator's stock valued at $32,000 after buying an additional 202 shares during the last quarter. ORG Partners LLC boosted its position in CVS Health by 418.9% in the second quarter. ORG Partners LLC now owns 467 shares of the pharmacy operator's stock valued at $32,000 after buying an additional 377 shares during the last quarter. Saudi Central Bank purchased a new stake in CVS Health in the first quarter valued at approximately $34,000. Finally, Livelsberger Financial Advisory purchased a new stake in CVS Health in the second quarter valued at approximately $35,000. Hedge funds and other institutional investors own 80.66% of the company's stock.

CVS Health Stock Down 0.2%

NYSE CVS opened at $76.94 on Thursday. The business has a fifty day moving average price of $71.68 and a 200 day moving average price of $67.52. CVS Health Corporation has a one year low of $43.56 and a one year high of $79.20. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.62 and a current ratio of 0.80. The company has a market cap of $97.59 billion, a P/E ratio of 21.49, a P/E/G ratio of 0.85 and a beta of 0.60.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The pharmacy operator reported $1.81 EPS for the quarter, beating the consensus estimate of $1.46 by $0.35. CVS Health had a return on equity of 10.51% and a net margin of 1.17%.The firm had revenue of $98.92 billion during the quarter, compared to the consensus estimate of $94.87 billion. During the same period in the prior year, the company earned $1.83 EPS. The firm's revenue was up 8.4% compared to the same quarter last year. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts anticipate that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Thursday, October 23rd will be paid a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 3.5%. The ex-dividend date of this dividend is Thursday, October 23rd. CVS Health's dividend payout ratio is currently 74.30%.

Analyst Ratings Changes

A number of equities research analysts recently commented on CVS shares. Bernstein Bank dropped their target price on CVS Health from $78.00 to $72.00 and set a "market perform" rating on the stock in a research report on Wednesday, July 16th. Zacks Research downgraded CVS Health from a "strong-buy" rating to a "hold" rating in a report on Monday, September 8th. Sanford C. Bernstein boosted their price target on CVS Health from $72.00 to $77.00 and gave the company a "market perform" rating in a report on Friday, September 5th. Morgan Stanley boosted their price target on CVS Health from $80.00 to $82.00 and gave the company an "overweight" rating in a report on Friday, August 1st. Finally, UBS Group raised CVS Health from a "neutral" rating to a "buy" rating and boosted their price target for the company from $67.00 to $79.00 in a report on Monday, August 18th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $79.20.

Insider Buying and Selling

In other CVS Health news, Director Anne A. Finucane sold 7,500 shares of the company's stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total value of $532,650.00. Following the completion of the sale, the director directly owned 22,156 shares in the company, valued at $1,573,519.12. This represents a 25.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.22% of the company's stock.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.